Literature DB >> 26851974

Effects of rivastigmine on visual attention in subjects with amnestic mild cognitive impairment: A serial functional MRI activation pilot-study.

Arun L W Bokde1, Enrica Cavedo2, Patricia Lopez-Bayo3, Simone Lista4, Thomas Meindl5, Christine Born5, Samantha Galluzzi6, Frank Faltraco7, Bruno Dubois8, Stefan J Teipel9, Maximilian Reiser5, Hans-Jürgen Möller3, Harald Hampel4.   

Abstract

A pilot study to investigate the effects of rivastigmine on the brain activation pattern due to visual attention tasks in a group of amnestic Mild Cognitive Impaired patients (aMCI). The design was an initial three-month double blind period with a rivastigmine and placebo arms, followed by a nine-month open-label period. All patients underwent serial functional magnetic resonance imaging (fMRI) at baseline, and after three and six months of follow-up. Primary endpoint was the effect of rivastigmine on functional brain changes during visual attention (face and location matching) tasks. There were five in the rivastigmine arm and two in the placebo arm. The face matching task showed higher activation of visual areas after three months of treatment but no differences compared to baseline at six months. The location matching task showed a higher activation along the dorsal visual pathway at both three and six months follow ups. Treatment with rivastigmine demonstrates a significant effect on brain activation of the dorsal visual pathway during a location matching task in patients with aMCI. Our data support the potential use of task fMRI to map specific treatment effects of cholinergic drugs during prodromal stages of Alzheimer's disease (AD).
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Cholinesterase inhibitors; Pharmaceutical therapy; Pharmacological fMRI; Visual attention

Mesh:

Substances:

Year:  2016        PMID: 26851974     DOI: 10.1016/j.pscychresns.2016.01.018

Source DB:  PubMed          Journal:  Psychiatry Res Neuroimaging        ISSN: 0925-4927            Impact factor:   2.376


  3 in total

Review 1.  Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology.

Authors:  Harald Hampel; Nicola Toschi; Claudio Babiloni; Filippo Baldacci; Keith L Black; Arun L W Bokde; René S Bun; Francesco Cacciola; Enrica Cavedo; Patrizia A Chiesa; Olivier Colliot; Cristina-Maria Coman; Bruno Dubois; Andrea Duggento; Stanley Durrleman; Maria-Teresa Ferretti; Nathalie George; Remy Genthon; Marie-Odile Habert; Karl Herholz; Yosef Koronyo; Maya Koronyo-Hamaoui; Foudil Lamari; Todd Langevin; Stéphane Lehéricy; Jean Lorenceau; Christian Neri; Robert Nisticò; Francis Nyasse-Messene; Craig Ritchie; Simone Rossi; Emiliano Santarnecchi; Olaf Sporns; Steven R Verdooner; Andrea Vergallo; Nicolas Villain; Erfan Younesi; Francesco Garaci; Simone Lista
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

2.  Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease.

Authors:  Enrica Cavedo; Michel J Grothe; Olivier Colliot; Simone Lista; Marie Chupin; Didier Dormont; Marion Houot; Stephane Lehéricy; Stefan Teipel; Bruno Dubois; Harald Hampel
Journal:  Sci Rep       Date:  2017-09-15       Impact factor: 4.379

Review 3.  Effects of pharmacological and nonpharmacological treatments on brain functional magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment: a critical review.

Authors:  Elisa Canu; Elisabetta Sarasso; Massimo Filippi; Federica Agosta
Journal:  Alzheimers Res Ther       Date:  2018-02-20       Impact factor: 6.982

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.